21 Aug Artiva Biotherapeutics
Posted at 18:04h
in
Nicholas Veomett, Vice President, Corporate Development
Oct. 6 | 3:00pm | FLW Ballroom F
San Diego, CA
(NASDAQ: ARTV)
Artiva is developing the most clinically advanced off-the-shelf approach to deep B-cell depletion for patients with autoimmune diseases. The Company is initiating a Phase 3 trial in refractory rheumatoid arthritis (RA) and conducting a Phase 2a study in multiple autoimmune diseases.